These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27074098)

  • 21. Oral delivery of all-trans retinoic acid mediated by liposome carriers.
    Cuomo F; Ceglie S; Miguel M; Lindman B; Lopez F
    Colloids Surf B Biointerfaces; 2021 May; 201():111655. PubMed ID: 33662750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol.
    Lu XY; Hu S; Jin Y; Qiu LY
    Drug Dev Ind Pharm; 2012 Mar; 38(3):314-22. PubMed ID: 21851312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved oral bioavailability of breviscapine via a Pluronic P85-modified liposomal delivery system.
    Zhou Y; Ning Q; Yu DN; Li WG; Deng J
    J Pharm Pharmacol; 2014 Jul; 66(7):903-11. PubMed ID: 24697705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific surface modification of liposomes for gut targeting of food bioactive agents.
    Zhang T; Xu X; Pan Y; Yang H; Han J; Liu J; Liu W
    Compr Rev Food Sci Food Saf; 2023 Sep; 22(5):3685-3706. PubMed ID: 37548603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral delivery of natural compounds by phospholipid vesicles.
    Manconi M; Caddeo C; Manca ML; Fadda AM
    Nanomedicine (Lond); 2020 Aug; 15(18):1795-1803. PubMed ID: 32698672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
    Roger E; Lagarce F; Garcion E; Benoit JP
    Nanomedicine (Lond); 2010 Feb; 5(2):287-306. PubMed ID: 20148639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The studies of N-Octyl-N-Arginine-Chitosan coated liposome as an oral delivery system of Cyclosporine A.
    Deng J; Zhang Z; Liu C; Yin L; Zhou J; Lv H
    J Pharm Pharmacol; 2015 Oct; 67(10):1363-70. PubMed ID: 26105005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Membrane Surface Modification Using Chitosan Hydrochloride and Lactoferrin on the Properties of Astaxanthin-Loaded Liposomes.
    Qiang M; Pang X; Ma D; Ma C; Liu F
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32019205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Archaeosomes facilitate storage and oral delivery of cannabidiol.
    Sedlmayr V; Horn C; Wurm DJ; Spadiut O; Quehenberger J
    Int J Pharm; 2023 Oct; 645():123434. PubMed ID: 37739097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Properties of liposomes coated with hydrophobically modified chitosan in oral liposomal drug delivery.
    Thongborisute J; Takeuchi H; Yamamoto H; Kawashima Y
    Pharmazie; 2006 Feb; 61(2):106-11. PubMed ID: 16526556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel.
    Zhang B; Xue A; Zhang C; Yu J; Chen W; Sun D
    Pharmazie; 2016 Jun; 71(6):320-6. PubMed ID: 27455550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes as biocompatible and smart delivery systems - the current state.
    Dymek M; Sikora E
    Adv Colloid Interface Sci; 2022 Nov; 309():102757. PubMed ID: 36152374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposome-based delivery system for vaccine candidates: constructing an effective formulation.
    Giddam AK; Zaman M; Skwarczynski M; Toth I
    Nanomedicine (Lond); 2012 Dec; 7(12):1877-93. PubMed ID: 23249332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers.
    Yue X; Dai Z
    Adv Colloid Interface Sci; 2014 May; 207():32-42. PubMed ID: 24368133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomal drug delivery systems--clinical applications.
    Goyal P; Goyal K; Vijaya Kumar SG; Singh A; Katare OP; Mishra DN
    Acta Pharm; 2005 Mar; 55(1):1-25. PubMed ID: 15907221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
    Joguparthi V; Anderson BD
    J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal Delivery Systems: Design Optimization and Current Applications.
    Abu Lila AS; Ishida T
    Biol Pharm Bull; 2017; 40(1):1-10. PubMed ID: 28049940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Archaeal lipids in oral delivery of therapeutic peptides.
    Jacobsen AC; Jensen SM; Fricker G; Brandl M; Treusch AH
    Eur J Pharm Sci; 2017 Oct; 108():101-110. PubMed ID: 28108360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media.
    Hu S; Niu M; Hu F; Lu Y; Qi J; Yin Z; Wu W
    Int J Pharm; 2013 Jan; 441(1-2):693-700. PubMed ID: 23089580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.